Pharmafile Logo

BMJ

- PMLiVE

Mastering Asynchronous Meetings: Open-Ended Questions – Impetus Digital Tip 1

Unlock the potential of asynchronous virtual meetings with the first tip from our "Top 10 Tips for Optimizing Asynchronous Virtual Meetings".

Impetus Digital

Top 10 Most Important Advisor Questions: Messaging and Branding

As part of our top 10 most important advisor questions that every brand team should keep in mind when designing virtual advisory board touchpoints, here's another one to keep in...

Impetus Digital

Amplifying Opinions of Patients & Caregivers for Higher Quality of Care

Pam Cusick, Senior Vice President of Rare Patient Voice, dives into diversity, equity, and inclusion in Pharma and clinical trials; ways to enhance the patient’s voice in their treatment journey...

Impetus Digital

How to Increase Engagement During Virtual Events

Tip #4 - How do you plan the agenda for your virtual event? We suggest to invite participant input to build and personalize the engagement. Check out our full top...

Impetus Digital

- PMLiVE

Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)

How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch

Innovative Trials

Impact of COVID-19 on the Biopsychosocial Model of Health

Dr. Tarry Ahuja, Manager of Program Development in Pharmaceutical Reviews and Senior RWE Advisor at CADTH, explores the impact of COVID-19 on the biopsychosocial model of health, key opportunities and...

Impetus Digital

CRM Design and Optimization for Life Science Organizations

John Leombruno, CEO of OkRx, shares how his company is working to improve PSP strategy and operations in Canada. He also discusses the impact of COVID-19 on PSPs, digital transformation, clinical...

Impetus Digital

- PMLiVE

Half of European cancer drug trials ‘biased’, says BMJ

Report says studies exaggerate benefits

Battling breast cancer with precision medicine (Part 1)

Laura Holmes Haddad is a breast cancer survivor. She made the incredibly brave decision to participate in a PARP inhibitor precision medicine trial. Here, the author and precision medicine advocate...

Blue Latitude Health

- PMLiVE

Victoza cuts cardiovascular risk in landmark study

Novo Nordisk’s diabetes therapy outcomes ‘beyond expectations’

AstraZeneca AZ global R&D corporate HQ

AZ’s tremelimumab fails mesothelioma trial

FDA-designated breakthrough therapy did not demonstrate increase in overall survival

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links